Skip to main content

Table 1 Demographic and baseline clinical characteristics of patients in the cyclophosphamide (CYC) and mycophenolate mofetil (MMF) groups

From: Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis

Characteristics CYC (n = 23) MMF (n = 34) P value for significance
Age, mean ± SD 46 ± 10.34 45.24 ± 13.87 0.82
Female, n (%) 18 (78.2) 31 (91.18) 0.24
Disease duration in years, mean ± SD 6.04 ± 5.96 4.19 ± 2.82 0.11
Clinical features, n (%)    
Breathlessness 21 (91.3) 30 (88.2) 0.53
Arthritis 23 (100) 28 (82.4) 0.07
Skin changes 21 (91.3) 30 (88.2) 0.53
Raynaud’s symptoms 17 (74) 18 (52.9) 0.16
Baseline FVC %, mean ± SD 48.74 ± 15.67 53.44 ± 13.69 0.23
Pulmonary artery hypertension, n (%) 2 (2.7) 4 (11.8) 0.63
Anti-scl-70-positive, n (%) 12 (52.17) 16 (47.18) 0.41
  1. FVC forced vital capacity